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pared to the “do nothing” strategy. To collect the information needed to process to
this assessment, two databases are used: a survey focused on equivalent incomes
(n3331) in a representative sample of the French population and a cost-effective-
ness model produced by the French National Authority for Health (HAS). RESULTS:
As preliminary results, we find that antihypertensive treatments in primary pre-
vention are efficient if the inequality aversion is 0, 1 or 2. However antihypertensive
treatments are not efficient anymore if it is decided to take a stronger degree of
inequality aversion of 3. Indeed, 20% of the poorest individuals would have an
increase of income if antihypertensive treatment were not prescribed and reim-
bursed by the national health insurance given their actual participation to public
health care expenses. CONCLUSIONS: These results may reflect issues raised by
the funding of health care in the French sytem.
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OBJECTIVES: The first single-pill triple antihypertensive therapy with valsartan-
(VAL), amlodipine(AML) and hydrochlorothiazide(HCTZ) is currently available. The
aim of this study was to compare the cost-effectiveness of the single-pill triple
combination with dual components in generic forms. METHODS: A Markov model
evaluating the cost-effectiveness of the single-pill triple combination against each
of the dual components was constructed. Two important assumptions have been
considered i) the cheaper available generics ii) effectiveness and adverse-events
were the same as in the original forms. To achieve the lowest available price for the
generic alternatives, three pills were necessary for the combination AML/VAL,
three for VAL/HCTZ and two for AML/HCTZ. It was also assumed that adherence
and Quality of Life (QoL) were similar as with single pill dual components. The time
horizon was lifetime. Effectiveness and costs were discounted at 3% rate. The
analysis was conducted from Greek third-party-payer perspective, in 2012(€).
RESULTS: The triple combination was expected to increase life expectancy by 0.14
to 0.49 years and QALYs by 0.12 to 0.38, comparing with its dual components. The
total cost of treatment with triple combination was estimated at €17,499 in com-
parison to €16,521 for AML/VAL, €14,959 for VAL/HCTZ and €11,269 for AML/HCTZ.
The incremental cost-effectiveness ratio (ICER) per Quality Adjusted Life Year
(QALY) gained with the triple combination versus the dual combinations VAL/AML,
VAL/HCT and AML/HCTZ was 13,251€, 28,067€ and 16,541€. There was a probability
of more than 80% for the triple combination to be cost-effective with an incremen-
tal cost effectiveness ratio (ICER) threshold of 25,000€/QALY gained.
CONCLUSIONS: The single-pill triple combination therapy with VAL/AML/HCTZ is
a cost-effective antihypertensive choice, compared to its dual components in ge-
neric forms. Moreover, this study may underestimate the cost-effectiveness of the
triple combination since a single-pill formulation would improve treatment adher-
ence and effectiveness more than the other comparators, requiring 2 to 3 different
pill intake.
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OBJECTIVES: The PLATO trial showed that in patients with acute coronary syn-
dromes (ACS) treatment with ticagrelor compared with clopidogrel significantly
reduced the rate of myocardial infarction, stroke, or death from vascular causes
without a significant increase in the rate of overall major bleeding. The aim of this
analysis is to estimate long-term cost-effectiveness of treating ACS patients with
ticagrelor from a Turkish health care perspective. METHODS: A two-part decision-
analytic model, including a one-year decision tree and a long-term Markov model,
was constructed to estimate lifetime costs, LYGs and QALYs of treating patients for
one year with ticagrelor plus acetylsalicylic acid (ASA) compared with clopidogrel
plus ASA. Event rates, health-care costs, and QALYs were estimated for the first
year by using individual-patient data from PLATO. The cost was calculated by
applying Turkish unit costs. For the second year onwards, necessary assumptions
and external data sources were utilized to extrapolate quality-adjusted survival
conditional on whether a non-fatal MI, a non-fatal stroke or no event occurred
during the first year. Probabilistic ssensitivity analyses were performed. The will-
ingness to pay threshold per QALY considered for the cost effectiveness analysis
was 3 times GDP per capita. RESULTS: Ticagrelor was associated with life expec-
tancy gains of 0.116 years primarily due to reduced rate of CV mortality and 0.101
additional QALYs and an incremental cost of 1662 TL compared to clopidogrel over
a life time horizon.The incremental cost per life year and QALY gained were 14 297
TL and 16 415 TL respectively compared to clopidogrel. Probabilistic sensitivity
analysis indicated  99% probability of ticagrelor being cost-effective compared
with clopidogrel at a willingness to pay of 52002 TL per QALY. CONCLUSIONS:
Treating ACS patients with ticagrelor instead of clopidogrel for one year is cost-
effective from the Turkish public health care perspective.
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OBJECTIVES: To perform pharmacoeconomic analysis of iloprost for critical limb
ischemia (CLI). METHODS: Direct medical and indirect costs were calculated for
iloprost20 mcg per day for 21 days vs typical practice of treating patients with CLI.
Direct medical costs included drug therapy, hospital treatment for amputations
and treating ulcers and were calculated from Russian health care system point of
view. Indirect costs included expected gross domestic product (GDP) loss due to the
disability of patients in working age. The expected number of amputations and
cases of ulcer treatment was calculated on the base of data from meta-analysis (T.
Loosemore, et al, 1994). Percentage of patients with CLI of working age was taken
from the retrospective study of treating CLI at Moscow hospitals. All prices were for
year 2012. To assess the sustainability of the study results the one-way sensitivity
analysis was performed,all costs were varied within 30% interval. RESULTS: Due
to less amputations(absolute risk reduction (ARR) 16%) and hospitalizations for
ulcer treatment (ARR 23%) iloprost saves €372 per patient for health care system. If
expected loss of GDP is taken into account the total costs saved are equal to €6190.
The results of one-way sensitivity analysis show that iloprost remains less costly
than typical practicein every scenario tested. CONCLUSIONS: Iloprost appeared to
be a cost-saving option when compared with typical practice of treating patients
with CLI in Russian health care system.
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OBJECTIVES: Patients with atrial fibrillation (AF) are at increased risk of stroke.
Furthermore, AF-related strokes are associated with greater severity, disability,
and mortality than strokes of other etiologies. Management with vitamin K antag-
onists (VKAs) like warfarin has been an effective and cost-effective strategy. How-
ever, their use requires regular monitoring and is associated with a significant risk
of bleeding, among other shortcomings. Dabigatran is a novel oral anticoagulant
associated with lower stroke and similar major hemorrhage rates compared to
warfarin. This study evaluated the cost-effectiveness of dabigatran for stroke pre-
vention in AF patients for the Dutch situation. METHODS: A Markov model was
developed using efficacy data extracted from the RE-LY registration study and cost
data from Dutch costing studies. The model contained the following health states:
AF, stroke or systemic embolism, transient ischemic attack, intracranial hemor-
rhage, myocardial infarction, pulmonary embolism, extracranial hemorrhage, mi-
nor bleeding, and death. The model allowed for new or recurrent events over the
lifetime of the patient. Additionally, factors such as subgroup-specific stroke risk,
drug discontinuation, and time in therapeutic range (a measure of quality of anti-
coagulation) were included in the model. Univariate and probabilistic sensitivity
analyses were conducted on the base-case incremental cost-effectiveness ratio
(ICER). RESULTS: In the base-case analysis, dabigatran-150mg compared to VKA
has an incremental cost of €3,057 and a QALY gain of 0.26, corresponding to an ICER
of €11,758/QALY. At an informal willingness-to-pay threshold of €50,000/QALY, the
probability that dabigatran is cost-effective was approximately 0.93. Sensitivity
analysis identified quality of anticoagulation care, drug-specific stroke risk, and
stroke cost as having the biggest impact on the ICER. CONCLUSIONS: Dabigatran
may be a cost-effective option for AF patients in The Netherlands. However, up-
dated estimates, specifically for anticoagulation care, stroke risk, and stroke cost in
The Netherlands, would further improve and reduce uncertainty surrounding the
results.
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OBJECTIVES: To conduct a systematic review of economic models of pharmaco-
logic stroke prevention in atrial fibrillation (SPAF). METHODS: We searched Med-
line, Embase, NHSEED and the Tuft’s Registry through May 2012. Included models
assessed pharmacologic SPAF using a Markov process or discrete event simulation
(DES), calculated both costs and effectiveness, and was published in English. Two
investigators independently screened models and extracted data. RESULTS:Twen-
ty-two models, published between 1995 and 2012, were identified. One model was
a DES, and the remainder Markov models. Eleven models used a structure similar
to Gage et al. (1995); five were derivatives of Sorensen et al. (2009), with the remain-
der using unique structures. Only 5 models had a non-CNS systemic embolism
health state. Models typically started at 65 or 70 years and followed patients for
their lifetime (e.g., 75 years of age). Inaccuracies in reporting of perspective ex-
isted; however, no model included indirect costs and all but one calculated quality-
adjusted life-years (QALYs). Twenty models included warfarin; however, only 50%
assessed the impact of INR control on conclusions. Most models included aspirin
alone (73%), ten evaluated newer anticoagulants, and three evaluated
clopidogrelaspirin. Comparative efficacy and safety data for warfarin vs. aspirin/
control models were often derived from meta-analyses; whereas, data for newer
agents came from a lone randomized trial. Models otherwise used similar sources
of non-drug dependent inputs. Eighty-two percent of reported base-case incre-
mental cost-effectiveness ratios (ICERs) were cost-effective ($50,000/QALY). Mod-
els typically found warfarin (vs. aspirin/no therapy), dabigatran and rivaroxaban
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(vs. warfarin), and apixaban (vs. aspirin) to be cost-effective; data on
clopidogrelaspirin (vs. aspirin) to be conflicting, and genotyped-warfarin and xi-
melagtran not cost-effective. CONCLUSIONS: Cost-effectiveness models of pharma-
cologic SPAF have been extensively published; but none have estimated the comparative
cost-effectiveness of newer agents. Models used similar structures and non-drug-specific
inputs, and commonly find innovator strategies to be cost-effective.
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OBJECTIVES: To undertake an economic evaluation of rivaroxaban relative to the
local standard of care, acenocoumarol, for stroke prevention in atrial fibrillation
(AF) patients with one or more risk factors.METHODS:A Markov model designed to
reflect the natural progression of AF patients through different health states was
developed and adapted to the Greek setting. The analysis was undertaken from a
payer perspective. Baseline event rates (adjusted to three month cycles) and rela-
tive treatment effects (RRs) were derived from the safety on treatment analysis of
the ROCKET AF study. Utility values for events were based on literature. A treat-
ment-related disutility of 0.05 was applied to acenocoumarol arm. Costs assigned
to each health state reflect local drug acquisition, monitoring, event management
and transportation costs and reflect the year 2012. An incremental cost effective-
ness ratio (ICER) per quality-adjusted-life year (QALY) gained was calculated. One-
way sensitivity analyses were conducted to identify key model drivers. Probabilis-
tic analysis was undertaken to deal with uncertainty. The horizon of analysis was
over patient life time and both cost and outcomes were discounted at 3.5%.
RESULTS: The average total cost of rivaroxaban-treated patients was €985 higher
compared to acenocoumarol. Rivaroxaban was associated with additional drug
acquisition costs (€5,275), however these were mainly offset by reduced monitoring
(€3,947) and event costs (€343). Moreover, rivaroxaban was associated with a 0.22
increment in QALYs leading to an ICER of €4,517/QALY gained. Sensitivity analyses
showed that the cost-effectiveness results are fairly robust with discontinuation
rate of rivaroxaban, acenocoumarol monitoring visits, acenocoumarol-related util-
ity decrement, RR for rivaroxaban versus acenocoumarol for stroke having the
highest impact on results. Probabilistic analysis revealed a high probability of ri-
varoxaban being cost-effective at a threshold of €30,000 or €40,000/QALY.
CONCLUSIONS: Rivaroxaban may represent a cost-effective option for the preven-
tion of stroke in AF patients with one or more risk factors.
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OBJECTIVES: In the PLATO study, ticagrelor significantly reduced the rate of myo-
cardial infarction (MI), stroke, or death from vascular causes without a significant
increase in the rate of overall major bleeding compared to Clopidogrel in the man-
agement of acute coronary syndrome (ACS) patients. We aimed to assess the long
term cost-effectiveness of ticagrelor versus clopidogrel in the management of ACS
patients in Hong Kong. METHODS: A Markov decision analytic model was used to
perform a cost-effectiveness analysis (CEA) of treating ACS patients for one year
with ticagrelor plus aspirin (group 1) compared with clopidogrel plus aspirin (group
2) from the Hong Kong health care provider perspective. The model simulates a
cohort of 45-year-old patients with ACS moving between different health status in
each Markov cycle of 1 year. The time horizon was lifetime (85 years old). Health
states included patient in ACS without event, myocardial infarction (MI), and death
from vascular cause. Outcome measures included lifetime costs, quality-adjusted
life years (QALYs) gained and incremental cost-effectiveness ratios (ICERs). Event
rates of group 1 are adopted from the PLATO study and rates of group 2 from the
Prince of Wales Hospital ACS Registry in Hong Kong. Probabilistic sensitivity anal-
yses using Monte Carlo simulations were conducted to assess parameter
uncertainty. RESULTS: The ICER for ticagrelor compared to clopidogrel in the treat-
ment of ACS was HK$34,441 (US$4,415) per QALY gained. For the subset of patients
with ST elevation myocardial infarction (STEMI) and non-ST elevation ACS
(NSTEACS), the ICERs per QALY gained were HK$ 33,402 (US$4,282) and HK$ 38,844
(4,980) respectively. Ticagrelor treatment strategy was cost-effective over 99% of
the Monte Carlo simulation using a cost-effectiveness threshold of 3 times gross
domestic product (GDP) per capita in Hong Kong. CONCLUSIONS: The treatment of
ACS patients with ticagrelor for 12 months is considered cost-effective compared
with clopidogrel from a health care provider perspective.
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OBJECTIVES: To evaluate the cost-effectiveness of the once daily oral anticoagu-
lant rivaroxaban for prevention of stroke and systemic embolism in non-valvular
atrial fibrillation (NVAF) patients from a UK payer perspective. METHODS: A
Markov model was developed to evaluate cost-effectiveness over a lifetime time
horizon. Costs and benefits were discounted at 3.5%. The patient population of
interest were AF patients with one or more risk factors currently treated with
warfarin. Clinical inputs were supplied from Safety-on-Treatment data from the
Phase III ROCKET trial or informed by systematically reviewed literature. The In-
tention-to-Treat (ITT) dataset was also used in a sensitivity analysis. Warfarin
efficacy data was adjusted to be reflective of the level of INR control found in
Western Europe and baseline risk was adjusted to be reflective of the UK popula-
tion. Economic inputs were based on unit costs from the BNF, PSSRU and NHS
Reference costs and resource use was from a dedicated observational study. Utility
inputs were taken from a systematic review and included baseline utilities for AF,
disutilities for clinical events and warfarin treatment. RESULTS: Base case analysis
versus warfarin resulted in a total per patient incremental cost of £705 and an
incremental QALY gain of 0.2459 with an estimated ICER of £2,869. The ITT analysis
returned an ICER of £3,404, with an incremental cost of £775 and an incremental
QALY of 0.2277. The sensitivity analyses found that the biggest drivers of the result
were discontinuation rates, warfarin monitoring cost in primary care, warfarin
disutility and frequency of warfarin monitoring. The PSA indicates that the prob-
ability of rivaroxaban being cost-effective at a willingness-to-pay threshold of
£20,000 is 97%. CONCLUSIONS: Rivaroxaban is a cost-effective alternative to war-
farin in the prevention of stroke and systemic embolism in NVAF patients with one
or more risk factors as evaluated from a UK payer perspective.
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OBJECTIVES: Statin monotherapy is the mainstay of LDL-C management for CHD
patients in Portugal, however several therapeutic options are available and pre-
dicted to have different clinical and economical impact. This analysis estimates the
Cost-Effectiveness (CE) of adding ezetimibe 10 mg (EZ10) to generic atorvastatin
10/20 mg (A10/20) against generic atorvastatin titration (A20/40) and against switch
to rosuvastatin 10/20 mg (R10/20) in Portuguese CHD patients who are currently
above LDL-C goal (2.5mmol/L). METHODS: The analysis was based on a previ-
ously published Markov model, employed to evaluate the life-time costs and health
outcomes, including life-years (LY) and quality adjusted life-years (QALY). The
model incorporated Framingham risk equations, Portuguese population character-
istics, CHD event rates, quality of life estimates, local resource use and due unit
costs. RESULTS: From 18 CHD patient risk profiles, discounted lifetime costs per
patient with A20/40, R10/20 and A10/20EZ10 treatment were €20,987, €23,134 and
€25,476, respectively. Average gain with A10/20EZ10 were 0.43 LY and 0.17 QALY
versus A20/40; and 0.38 LY and 0.15 QALY versus R10/20. Thus, the incremental
costs per QALY gained by switching patients from A10/20 to A20/40EZ10 were
€26,435 and €15,907 against titrating to A20/40 and switch to R10/20, respectively.
Based on the Portuguese CE acceptability frontier with a willingness-to-pay value
of €30.000/QALY gained, A10/20EZ10 is projected to be CE for CHD patients on
secondary prevention. CONCLUSIONS: In the Portuguese CHD patients not at
LDL-C goal treated with A10/20, adding EZ10 is CE when compared with atorvasta-
tin titration or switching to rosuvastatin. Moreover, the expected erosion of atorv-
astatin generics’ price will favor CE ratio of A10/20EZ10 versus R10/20 switch.
Thus, ezetimibe is effective in lowering LDL-C, and based on the analysis con-
ducted, is projected to reduce CV events, improve quality of life, and is cost-effec-
tive by commonly used criteria in Portugal.
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OBJECTIVES: Recently, the first single pill (SPC) triple-combination antihyperten-
sive therapy with valsartan(VAL), amlodipine(AML) and hydrochlorothiazide(H-
CTZ) has been available. The aim of this study is to compare the cost-utility of
single pill triple combination with each of the dual combinations deriving from the
same components in patients with moderate to severe hypertension. This is the
first study to evaluate the CUA of this SPC. METHODS: A Markov model with eight
health states was constructed. The short-term effect of antihypertensive treat-
ment on blood pressure was extrapolated through the Hellenic SCORE and
Framingham risk equations in order to estimate the long-term survival and qual-
ity-adjusted life-years (QALYs). Pharmaceutical cost was extracted from the official
price bulletins. Cost of adverse events was derived from international literature,
reflecting €2012. Outcomes and costs were evaluated over lifetime, divided into
annual cycles and were discounted at 3.0%. The analysis was conducted from a
Greek third-party-payer perspective. RESULTS: The cost of treatment with triple
combination was estimated at €17,499 in comparison to €18,203 for AML/VAL,
€16,069 for VAL/HCTZ and €11,945 for AML/HCTZ. The QALYs of the triple combi-
nation were 12.76 vs. 12.64, 12.61 and 12.38 of double combinations respectively,
resulting in incremental QALYs gained of triple vs. double combination in 0.12, 0.15
and 0.38 respectively. The incremental cost-effectiveness ratio (ICER) per QALY
gained with the triple combination versus VAL/HCTZ and AML/HCTZ was far lower
than the Greek GDP per capita (9,649€, 14,581€, respectively), while the triple com-
bination was found to be dominant in comparison with AML/VAL. Extensive sen-
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